They knew about the limited bioavailability from the beginning. They had strong pre-clinical data. They did not have G-3 available. They had reasonable expectations that they could find an effective G-1 oral dose. Got very close. My peeve is that they did not go with combinations at the beginning. Is what it is.
News 
Market Data 
Discover 
